Teriflunomide treatment reduces B cells in patients with MS.

OBJECTIVE

To study the immunomodulatory effect of teriflunomide on innate and adaptive immune cell populations through a pilot, open-label, observational study in a cohort of patients with relapsing-remitting MS.

METHODS

Blood lymphocytes were isolated from 10 patients with MS before and after 3 or 12 months of treatment. Adaptive and innate immune cell subsets were analyzed by flow cytometry as follows: B cells (memory, regulatory, and mature subsets), T cells (effector and regulatory subsets), and natural killer (NK) cells (CD56 and CD56 subsets).

RESULTS

Our results show that teriflunomide significantly reduces absolute counts of total CD19 B cells and mature and regulatory B-cell subsets. T cells were affected to a lesser extent, with a trend in reduction of absolute counts for both T effector CD4 cells (Th1, Th17 and Th1/17) and T regulatory CD8 and CD4 cells. Teriflunomide had no detectable effect on NK-cell numbers.

CONCLUSIONS

In our small cohort, teriflunomide treatment affects mainly and significantly on B-cell numbers, while having a milder effect on T-cell numbers. Larger cohorts are necessary to confirm these findings and understand the effect of teriflunomide on the functionality of these cells.